Group 1: Financial Performance - The overall gross margin for the company's proprietary brand is approximately 50% [2] - In 2024, the revenue from proprietary brands is expected to grow nearly 30% year-on-year, indicating a strong growth trend [2] - Currently, the revenue share from proprietary brands is relatively low, but it is anticipated to increase as the company invests more in sales resources and expands its product pipeline [2] Group 2: Sales Strategy - The company maintains a complementary product structure between proprietary and third-party brands, promoting mutual development [2] - By integrating market channel resources, the company aims to drive simultaneous growth for both proprietary and third-party brands through solution-oriented sales [2] Group 3: Share Buyback - In 2024, the company initiated a share buyback plan, utilizing 25,987,076 CNY to repurchase 927,600 shares, intended for equity incentives or employee stock ownership plans [2] - A new share buyback plan is set to use no less than 15 million and no more than 30 million CNY of its own funds for share repurchase, aimed at cancellation and reduction of registered capital [2] Group 4: Market Expansion - The company's business is primarily focused on the domestic market, with plans to accelerate the international expansion of proprietary brand products based on product development and domestic sales performance [2] - In 2024, the company established a presence in Singapore and is actively enhancing product visibility through online marketing and participation in offline exhibitions [2] Group 5: M&A Strategy - The company is focused on building a one-stop platform and enhancing R&D capabilities, aligning with its "two extremes strategy" [3] - Continuous investment in marketing, product line expansion, information technology, supply chain capabilities, and R&D is aimed at improving service capabilities and research strength [3] - The company seeks potential upstream and downstream acquisition targets that align with its existing business, particularly in antibody-related applications, to ensure sustainable development [3]

证券代码：301166 证券简称：优宁维 公告编号：2025-060 关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 上海优宁维生物科技股份有限公司 上海优宁维生物科技股份有限公司（以下简称"公司"或"优宁维"）于 2025 年 2 月 17 日召开第四届董事会第三次会议和第四届监事会第三次会议，2025 年 3 月 7 日召开 2025 年第二次临时股东大会，审议通过了《关于使用闲置募集资 金及自有资金进行现金管理的议案》，同意公司及并表范围内的子孙公司在不影 响募集资金投资项目建设、不影响公司正常生产经营及确保资金安全的情况下， 使用不超过人民币 30,000 万元（含本数）的闲置募集资金及不超过人民币 150,000 万元（含本数）的自有资金进行现金管理，使用期限自 2025 年 3 月 9 日起 12 个 月内有效。公司独立董事和保荐机构均发表了同意意见。具体内容详见公司分别 于 2025 年 2 月 19 日和 2025 年 3 月 8 日刊载于巨潮资讯网（www.cninfo.com.cn） 的相关公告。 ...

Group 1: Market Demand and Recovery - The recovery of downstream demand in the industry is evident in certain segments, but overall industry recovery will take time [2] - The company observes that specific segments, such as ADC, are performing better than last year [2] Group 2: Product Structure and Revenue Growth - The company operates as a one-stop service provider in life sciences, offering reagents, consumables, instruments, and laboratory services, integrating both well-known and self-branded products [2] - Revenue from the company's self-branded products is expected to grow nearly 30% year-on-year in 2024, indicating a strong growth trend [2] Group 3: Profit Margin Trends - The gross margin for the company's agency business faces short-term downward risks, but long-term prospects suggest a potential rebound as channels evolve and the industry clears [2] - The self-branded business is expected to maintain a stable gross margin, contributing to an overall improvement in the company's gross margin as its revenue share increases [2] Group 4: Market Strategy - The company plans to enrich and optimize its product system to better meet diverse customer needs, focusing on both third-party and self-branded products [2] - The company aims to accelerate the domestic and international expansion of its self-branded products, leveraging 20 years of experience in life sciences to provide comprehensive solutions [2] - Information technology will be utilized to enhance business and management efficiency, improving customer service [2]

Core Viewpoint - The company, Shanghai Youningwei Biotechnology Co., Ltd., has approved the use of idle funds for cash management, allowing the investment of up to RMB 300 million in idle raised funds and RMB 1.5 billion in self-owned funds for a period of 12 months starting from March 9, 2025 [1]. Group 1: Cash Management Details - The company plans to invest in structured deposits and low-risk non-principal guaranteed financial products, which are categorized as low-risk investment types [1]. - The expected annualized returns for various structured deposits range from 0.59% to 2.8186% [5]. - The total amount of raised funds (including oversubscribed funds) used for structured deposits as of July 4, 2025, is RMB 195 million, while the amount of self-owned funds used is RMB 850 million [2]. Group 2: Investment Breakdown - Specific structured deposit investments include: - RMB 2 million with Industrial Bank, expected return of 2.10% [5]. - RMB 3 million with China Merchants Bank, expected return of 2.00%-2.30% [5]. - RMB 4 million with Bank of China, expected return of 0.5900% or 2.8186% [5]. - RMB 10 million with Industrial Bank, expected return of 1.20% or 2.15% [5]. - The company has also engaged with various banks for structured deposits, including Ping An Bank and Shanghai Pudong Development Bank, with amounts ranging from RMB 1 million to RMB 25 million [2][3][4]. Group 3: Risk Management and Operational Impact - The company emphasizes that cash management will not affect its normal operations and aims to enhance fund utilization efficiency while ensuring the safety of the principal [1]. - Risk control measures include maintaining close contact with financial institutions and conducting audits to verify the cash management fund usage [1].

证券代码：301166 证券简称：优宁维 公告编号：2025-059 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 上海优宁维生物科技股份有限公司（以下简称"公司"或"优宁维"）于 2025 年 2 月 17 日召开第四届董事会第三次会议和第四届监事会第三次会议，2025 年 3 月 7 日召开 2025 年第二次临时股东大会，审议通过了《关于使用闲置募集资 金及自有资金进行现金管理的议案》，同意公司及并表范围内的子孙公司在不影 响募集资金投资项目建设、不影响公司正常生产经营及确保资金安全的情况下， 使用不超过人民币 30,000 万元（含本数）的闲置募集资金及不超过人民币 150,000 万元（含本数）的自有资金进行现金管理，使用期限自 2025 年 3 月 9 日起 12 个 月内有效。公司独立董事和保荐机构均发表了同意意见。具体内容详见公司分别 于 2025 年 2 月 19 日和 2025 年 3 月 8 日刊载于巨潮资讯网（www.cninfo.com.cn） 的相关公告。 现将公司近日使用部分闲置自有资金进行现金管理的相关事宜公告如下： | 购买 ...

上海优宁维生物科技股份有限公司 关于股东减持计划实施完成的公告 上海创业接力泰礼创业投资中心（有限合伙）、上海泰礼创业投资管理有限公 司－上海含泰创业投资合伙企业（有限合伙）保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 上海优宁维生物科技股份有限公司（以下简称"公司"或"本公司"）于2025年 4月22日披露了《关于股东减持股份的预披露公告》（公告编号：2025-039），公 司股东上海创业接力泰礼创业投资中心（有限合伙）（以下简称"泰礼投资"）及 其一致行动人上海泰礼创业投资管理有限公司－上海含泰创业投资合伙企业（有 限合伙）（以下简称"含泰投资"）计划在前述公告披露之日起15个交易日后的3 个月内合计减持不超过2,572,172股，减持比例不超过公司扣除回购专户股份后总 股本的3%。2025年5月19日至2025年5月20日，泰礼投资、含泰投资合计减持 171,500股，合计持股比例下降至7.00%；2025年5月21日至2025年6月5日，泰礼投 资、含泰投资合计减持1,208,500股，合计持股比 ...

证券代码：301166 证券简称：优宁维 公告编号：2025-057 一、回购公司股份的进展情况 截至 2025 年 6 月 30 日，公司通过股份回购专用证券账户以集中竞价交易方 式累计回购公司股份 0 股，占公司总股本的 0%，公司暂未实施本次股份回购。 本次回购股份符合相关法律、行政法规、规范性文件及公司回购股份方案等 有关规定。 二、其他说明 公司回购股份符合《深圳证券交易所上市公司自律监管指引第 9 号——回购 股份》及公司回购股份方案的相关规定，具体如下： 1、公司未在下列期间回购公司股份： 上海优宁维生物科技股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 上海优宁维生物科技股份有限公司(以下简称"公司")于 2025 年 4 月 10 日召 开第四届董事会第四次会议、第四届监事会第四次会议，于 2025 年 5 月 13 日召 开 2024 年度股东大会，审议通过了《关于回购公司股份方案的议案》，同意公 司使用不低于人民币 1,500 万元（含本数），不高于人民币 3,000 万元（含本数） 的自有资金以 ...

Core Viewpoint - On June 30, a total of 31 listed companies had their restricted shares unlocked, with a total market value of approximately 31.50 billion yuan [1]. Group 1: Unlocking Details - The specific details of the restricted share unlocks include: - Meili Ecology (000010): 239 million shares from A-share issuance to original shareholders - Xingrong Environment (000598): 4.926 million shares from equity incentive lock-up - Yueyang Xinchang (000819): 526,800 shares from equity incentive lock-up - Gaohong Co., Ltd. (000851): 4.944 million shares from equity incentive lock-up - Zhongyan Chemical (600328): 470,460 shares from equity incentive lock-up - Yangnong Chemical (600486): 115,480 shares from equity incentive lock-up - Kangyuan Pharmaceutical (600557): 2.6093 million shares from equity incentive lock-up - Keda Technology (002518): 1.3953 million shares from equity incentive lock-up - Longci Technology (300835): 562,700 shares from equity incentive lock-up - Weiming Environmental Protection (603568): 3.129 million shares from equity incentive lock-up - Dongrui Co., Ltd. (001201): 486,400 shares from A-share issuance to original shareholders - Sanwei Co., Ltd. (603033): 1.183 million shares from equity incentive lock-up - Naer Co., Ltd. (002825): 140,000 shares from equity incentive lock-up - Jinyinhe (300619): 1.6248 million shares from A-share issuance to legal persons - Tianyuan Environmental Protection (301127): 14.6 million shares with extended lock-up period - Youningwei (301166): 40.6188 million shares with extended lock-up period - Xutian Salt Industry (600929): 3.033 million shares from equity incentive lock-up - Keli Sensor (603662): 722,800 shares from equity incentive lock-up - Gongniu Group (603195): 641,200 shares from equity incentive lock-up - Fuyuan Pharmaceutical (601089): 27.5 million shares from pre-issue lock-up - Xinbang Intelligent (301112): 7.4097 million shares from pre-issue lock-up - Shanghai Port Bay (605598): 29,400 shares from equity incentive lock-up - Dingjide (603255): 507,500 shares from equity incentive lock-up - United Precision (001268): 6.154 million shares from pre-issue lock-up - Pinggao Co., Ltd. (688227): 48.9585 million shares - Chunli Medical (688236): 20.9 million shares - Zhongwulian (688297): 40.3 million shares - Lais Information (688631): 163,480 shares - Shichuang Energy (688429): 200,000 shares - Xindong Link (688582): 220,840 shares - Aike Saibo (688719): 100,000 shares [2].

Group 1 - Shanghai Youning Biological Technology Co., Ltd. won a bid for reagent procurement from Shandong First Medical University, with a total transaction amount of 7403.70 RMB [1] - The procurement includes multiple items, all supplied by CST, a manufacturer based in the United States [2] - Each item has a unit price of 2467.90 RMB, with a delivery requirement of within 7 days after contract signing [1][2] Group 2 - The items procured include K63-linkage Specific Polyubiquitin, Phospho-NF-κB p65, and NLRP3 Rabbit mAbs, each with a specification of 100ul [2] - The procurement emphasizes standard service for warranty and after-sales support [1][2] - Payment is contingent upon successful delivery and acceptance of the goods [1]

证券代码：301166 证券简称：优宁维 公告编号：2025-056 上海优宁维生物科技股份有限公司 关于首次公开发行前部分已发行股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 3、本次拟解除限售的股份原定上市流通日为 2025 年 6 月 28 日，因 2025 年 6 月 28 日为非交易日，故上市流通日期顺延至下一交易日 2025 年 6 月 30 日（星 期一）。 一、首次公开发行股份概况 经中国证券监督管理委员会《关于同意上海优宁维生物科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2021〕3556 号）同意注册，并经深圳 证券交易所《关于上海优宁维生物科技股份有限公司人民币普通股股票在创业板 上市的通知》（深证上〔2021〕1336 号）同意，公司首次向社会公众公开发行人 民币普通股（A 股）股票 21,666,668 股，于 2021 年 12 月 28 日在深圳证券交易 所上市交易。首次公开发行前总股本 65,000,000 股，首次公开发行股票完成后公 司总股本为 86,666,668 股，其 ...